Search
for
Sort by
Research 481–510 of 1000+
- Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up
- Gynostemma pentaphyllum Hydrodistillate and Its Major Component Damulin B Promote Hair Growth-Inducing Properties In Vivo and In Vitro via the Wnt/β-Catenin Pathway in Dermal Papilla Cells
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Congenital Adrenal Hyperplasia
- Андроген-опосередковані й андрогенонезалежні причини алопеції та акне в жінок. Огляд літератури
- Acne Vulgaris
- Use of pegvaliase in the management of phenylketonuria: Case series of early experience in US clinics
- Non-Scarring Alopecia in Females: A Comprehensive Review
- The JAK/STAT signaling pathway: from bench to clinic
- Essential Oils and Their Single Compounds in Cosmetics—A Critical Review
- Phytochemistry, pharmacological activity, and potential health benefits of Glycyrrhiza glabra
- Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Ethnodermatological use of medicinal plants in India: From ayurvedic formulations to clinical perspectives – A review
- An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
- Dupilumab side effect in a patient with atopic dermatitis: a case report study
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Consensus on the treatment of alopecia areata – Brazilian Society of Dermatology
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies
- A review of environmental and health effects of synthetic cosmetics
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
- Adverse Events in Isotretinoin Therapy: A Single-Arm Meta-Analysis
- “A thing of beauty is a joy forever”. Plants and plant-based preparations for facial care in Suriname
- Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long‐Term Multicentre Real‐World Study
- A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial
- Cytokine-Targeting Biologic Therapies for Alopecia Areata: A Comprehensive Review of Mechanism of Action, Clinical Efficacy, and Adverse Events
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata